RECRUITINGOBSERVATIONAL
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
About This Trial
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
2. 20 years
3. Patients requiring systemic chemotherapy with curative intent
4. Written willing to sign a consent form
Who Should NOT Join This Trial:
1. Myeloid malignancy
2. Multiple myeloma
3. Patients do not require systemic chemotherapy with curative intent
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
2. 20 years
3. Patients requiring systemic chemotherapy with curative intent
4. Written informed consent
Exclusion Criteria:
1. Myeloid malignancy
2. Multiple myeloma
3. Patients do not require systemic chemotherapy with curative intent
Treatments Being Tested
DRUG
Chemotherapy
Systemic chemotherapy with curative intent
Locations (1)
Samsung Medical Center
Seoul, South Korea